血清チロトロピン:甲状腺機能のファーストライン差別テスト.

A sociogram for the cranes of the world.

Behavioural processes·2014

Support for the EUCAST and revised CLSI fluconazole clinical breakpoints by Sensititre® YeastOne® for Candida albicans: a prospective observational cohort study.

The Journal of antimicrobial chemotherapy·2014

Candidemia following solid organ transplantation in the era of antifungal prophylaxis: the Australian experience.

Transplant infectious disease : an official journal of the Transplantation Society·2009

The effects of rat corticotrophin-releasing factor-41 Peptide fragments on bioassay and immunoassay determination of corticotrophin-releasing factor-41 levels.

Journal of neuroendocrinology·2009

Corticotrophin-releasing factor-41 in the human and rat-utility of a highly sensitive enzyme amplified immunometric assay.

Journal of neuroendocrinology·2009

Recommendations for the treatment of established fungal infections.

Internal medicine journal·2008

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Lancet (London, England)·2026

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

Lancet (London, England)·2026

Advancing the relevance of clinical trials for older patients.

Lancet (London, England)·2026

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

Lancet (London, England)·2026

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Lancet (London, England)·2026

Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

Lancet (London, England)·2026

Tertiary lymphoid structures as biomarkers and therapeutic targets in neoadjuvant cancer immunotherapy.

Frontiers in immunology·2026

The hidden tumour: giant anterior mediastinal thymolipoma, an incidental finding.

Polish journal of pathology : official journal of the Polish Society of Pathologists·2026

FADS1-mediated Efferocytosis in Tumor-Associated Macrophages Shapes an Immunosuppressive Microenvironment in Gastric Cancer.

Cellular and molecular life sciences : CMLS·2026

The tumoural landscape of lymphocytes and immune pathways in immunotherapy-treated melanoma patients.

Genes and immunity·2026

Strategic engineering B cell immunity for cancer immunotherapy.

Journal of controlled release : official journal of the Controlled Release Society·2026

An Endometrioid Carcinoma With an Adenoma Malignum-like Pattern of Invasion: New Insight into Molecular Features.

International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists·2026

関連する実験動画

血清チロトロピン:甲状腺機能のファーストライン差別テスト.

関連する概念動画

A sociogram for the cranes of the world.

Support for the EUCAST and revised CLSI fluconazole clinical breakpoints by Sensititre® YeastOne® for Candida albicans: a prospective observational cohort study.

Candidemia following solid organ transplantation in the era of antifungal prophylaxis: the Australian experience.

The effects of rat corticotrophin-releasing factor-41 Peptide fragments on bioassay and immunoassay determination of corticotrophin-releasing factor-41 levels.

Corticotrophin-releasing factor-41 in the human and rat-utility of a highly sensitive enzyme amplified immunometric assay.

Recommendations for the treatment of established fungal infections.

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

Advancing the relevance of clinical trials for older patients.

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

Tertiary lymphoid structures as biomarkers and therapeutic targets in neoadjuvant cancer immunotherapy.

The hidden tumour: giant anterior mediastinal thymolipoma, an incidental finding.

FADS1-mediated Efferocytosis in Tumor-Associated Macrophages Shapes an Immunosuppressive Microenvironment in Gastric Cancer.

The tumoural landscape of lymphocytes and immune pathways in immunotherapy-treated melanoma patients.

Strategic engineering B cell immunity for cancer immunotherapy.

An Endometrioid Carcinoma With an Adenoma Malignum-like Pattern of Invasion: New Insight into Molecular Features.

関連する実験動画

血清チロトロピン:甲状腺機能のファーストライン差別テスト.

関連する概念動画

関連記事